Testing Temozolomide and M1774 Combination
Phase 1/2
58
about 3.4 years
18+
23 sites in CA, CT, IL +6
About this study
This trial is testing the safety and effectiveness of a combination treatment with temozolomide and M1774 in patients with advanced cancer. The goal is to determine the best dose of this combination and how well it works in treating different types of cancer that has spread to other parts of the body.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Temozolomide
- 2.Take Tuvusertib
- 3.Undergo Biopsy Procedure
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
temozolomide
injection, intravenous
Primary: Dose limiting toxicity and the maximum tolerated dose
Secondary: Objective response rate (ORR), Overall survival (OS), Progression free survival (PFS), Rate of >= grade 3 adverse events (AE)
biopsy, diagnostic, imaging
Oncology